Journal of Innovative Research in Health Sciences, 2(1), 2026, 34-39

Reviews Article

Loop-Mediated Isothermal Amplification (LAMP) for Diagnosis of Endemic Febrile Illnesses in Resource-Limited Settings: A Narrative Review of Clinical Performance and Implementation Challenges

Dina Fauziah[1*]

[1]**Faculty of Medicine, Universitas Negeri Malang, Malang, Indonesia**

*Corresponding author:
Name: Dina Fauziah
Address: Jl. Tirtomulyo V, Kota Malang
Email address: dina.fauziah.fk@um.ac.id

Abstract

Endemic Febrile Diseases (EFDs) such as dengue, malaria, and leptospirosis pose a significant diagnostic challenge in resource-limited settings (RLCs) due to overlapping clinical symptoms, leading to misdiagnosis and inappropriate treatment. While quantitative PCR (qPCR) offers high sensitivity, its reliance on complex hardware and stable electricity makes it unsuitable for RLCs. This narrative review evaluates the clinical performance of Loop-Mediated Isothermal Amplification (LAMP) as a viable alternative and explores recent innovations addressing its implementation barriers.

LAMP utilizes a strand-displacing polymerase and 4–6 primers to achieve rapid, 10^9-fold amplification at a constant temperature, eliminating the need for a thermal cycler. Clinically, LAMP demonstrates high diagnostic accuracy, notably for Dengue Virus (DENV) and Malaria, offering comparable sensitivity to PCR but with operational advantages suitable for elimination programs. However, its adoption has been hampered by the complexity of nucleic acid extraction, the requirement for a cold chain for reagent stability, and issues of non-specific amplification and contamination.

To overcome these hurdles, transformative innovations have been developed, including "Direct LAMP" for extraction-free testing, lyophilization for cold-chain independence, and the use of biochemical additives (e.g., PEG) and hardware solutions (e.g., chip-based platforms) to enhance specificity and prevent contamination. Field implementation, such as the EXPANDIA project, confirms LAMP's operational superiority in RLCs, highlighting its resilience during power outages and its potential for decentralized diagnostics. In conclusion, LAMP is maturing into a robust, point-of-care platform crucial for strengthening infectious disease surveillance and achieving universal health coverage.

Key Words: LAMP, Febrile, PCR, Low-Resource, Diagnostic

Introduction

Endemic febrile diseases (EFDs) like malaria, dengue, and emerging zoonoses like Mpox share overlapping clinical features such as fever, malaise, and headache that make syndromic management unreliable. In regions where these pathogens coexist, misdiagnosis leads to inappropriate antibiotic use, increased healthcare costs, and preventable mortality. Molecular diagnostics offer the sensitivity required for early detection, but the "Gold Standard" Quantitative PCR (qPCR) requires thermal cyclers, stable electricity, and precise sample preparation.

LAMP, first described by Notomi and colleagues, utilizes a strand-displacing polymerase (Bst) and a set of 4–6 primers to achieve 10^9-fold amplification in under an hour at a constant temperature[1]. This "isothermal" nature removes the need for complex hardware, yet the journey for developing point-of-care-testing (POCT) has been hampered by sample preparation complexities and reagent instability[2]. The purpose of

ISSN: 3123-3708

this review is to evaluate the diagnostic performance of LAMP in tropical settings, outline its foundational working principles, and explore the recent innovations overcoming implementation barriers in resource-limited settings.

Clinical Evidence and Performance Comparison

The use of LAMP has been explored for the diagnosis of endemic diseases such as dengue, malaria, and leptospira. A recent meta-analysis showed that LAMP for Dengue Virus (DENV) has high diagnostic accuracy in serum samples, even surpassing antigen rapid tests [3]. The sensitivity of DENV LAMP is 0.83 (0.80-0.85) and specificity is 0.95 (0.91-0.98). The Positive Likelihood Ratio (PLR) is 14.31 (7.82-26.20) and the Negative Likelihood Ratio (NLR) is 0.15 (0.07-0.31). The Area Under the Curve (AUC) SROC reached 0.9633 [3,4]. These findings support LAMP as a highly accurate and reliable diagnostic test.

Etiologies of fever in Indonesia can also be due to parasitic infections such as malaria. LAMP provides a molecular diagnostic alternative to support microscopy results, capable of detecting parasitemia as low as 1–2 parasites/μL [5]. Although RDTs are widely used, these methods are susceptible to false positives due to the persistence of HRP2 antigen and false negatives due to deletion of the pfhrp2/3 gene. LAMP offers comparable sensitivity to PCR but with the operational speed required for elimination programs. The integration of lateral flow readout further enhances the portability of this molecular tool for use in rural endemic areas.

Diagnosing bacterial infections, particularly Leptospirosis, presents challenges in regions like the Philippines and Indonesia. This is because the clinical symptoms are non-specific and often mimic those of other diseases such as dengue fever or malaria. Clinical assessment by doctors often leads to overdiagnosis, with specificity as low as 33.7%. The development of LAMP targeting the rrsp gene in pathogenic Leptospira provides a sensitivity of around 43.6% in the blood samples of hospitalized patients, but this figure increases significantly to 84.6% in patients with positive culture results [6].

LAMP Working Principles

The technical superiority of LAMP is rooted in its highly specific primer design and the enzymatic activity of Bst (Bacillus stearothermophilus) DNA polymerase. Unlike PCR, which typically uses only two primers, the LAMP system requires at least four to six primers that recognize six to eight different regions on the target sequence [2]. This multi-primer approach ensures extraordinary analytical specificity, as all primers must hybridize precisely for the reaction to proceed to the exponential amplification stage.

The process begins with the hybridization of the forward inner primer (FIP) to the target sequence to initiate the synthesis of the complementary strand. This step is immediately followed by the annealing of the forward outer primer (F3), which triggers strand displacement, releasing a single strand of DNA that is bound to FIP. This single strand then becomes the template for the backward primers (BIP and B3), which ultimately form the characteristic dumbbell-shaped DNA structure of the LAMP method [2]. Through self-priming and 3' end elongation mechanisms, a complex amplicon resembling a cauliflower-like structure is produced, containing numerous target repeat sequences, reaching up to 10^9 copies in less than an hour [1].

The use of additional loop primers (LF and LB) significantly accelerates the

ISSN: 3123-3708

reaction by providing extra primer binding sites within the stem-loop structure [1]. This reaction speed allows for the emergence of visual detection methods impossible with conventional PCR, such as observing the turbidity produced from magnesium pyrophosphate precipitation or color changes via pH indicators like phenol red or metal ion indicators like calcein [2]. Considering the importance of primers in determining the success of target DNA amplification in LAMP, special attention is needed in the design process. Effective LAMP primer design is constrained by strict thermodynamic and structural requirements. The use of bioinformatics tools such as PrimerExplorer and NEB LAMP Primer Design Tool is crucial for managing this complexity [7]. Key parameters in developing a robust assay are summarized in table 1.

Table 1. Primer Design Caveat [7]

Parameter	Recommended Range/Value	Technical Significance
Primer Length	18–25 nt (F3, B3); 40–60 nt (FIP, BIP)	Ensures stable hybridization and loop formation.
Melting Temperature (Tm)	64-66°C (F1c/B1c); 59-61°C (F2/B2/F3/B3)	Maintains the balance of the isothermal reaction.
GC Content	40%–60% (Ideal 50%–60%)	Balances structural stability to denaturation efficiency.
ΔG at 3’ End	-4 kcal/mol or less	Minimizes primer-dimer formation and non-specific annealing.
Spacing (F2 to B2)	120–160 bp	Optimizes the size of the initial dumbbell structure.

Technical Hurdles in Resource-Limited Settings

Traditionally, the most expensive and time-consuming part of a molecular test is nucleic acid extraction. In resource-limited clinics (RLCs), the requirement for centrifuges and spin-columns creates a physical barrier to testing. Research indicates that while magnetic bead extraction provides the highest purity, it is often too "high-tech" for rural clinics. Simplified methods like boiling or alkaline lysis have been explored; however, these often leave behind proteins and salts that can inhibit the Bst enzyme, leading to a loss in sensitivity compared to laboratory-purified samples [8].

Moreover, most LAMP reagents are traditionally shipped on dry ice and stored at -20°C [9]. In many endemic regions, "last-mile" delivery lacks reliable refrigeration. Without stabilization, the Bst polymerase and Reverse Transcriptase (RT) enzymes lose activity within hours of exposure to tropical temperatures [10]. This has historically limited LAMP to centralized urban laboratories, defeating the purpose of a POCT test.

The fundamental challenge in developing successful LAMP assays stems from its highly intricate primer architecture. This significant complexity in the primer mix drastically increases

ISSN: 3123-3708

the combinatorial possibilities for non-specific interactions. Additionally, residual contamination, in which amplicons from previous reactions contaminate new tubes, is particularly problematic for LAMP due to its extreme amplification efficiency [11]. Consequently, the risk of primer-dimerization and the formation of other spurious amplification products is substantially elevated compared to PCR. This non-specific amplification is a major source of false-positive signals, a complication that is particularly critical in point-of-care diagnostics when utilizing highly sensitive but non-specific detection methods.

Technical Hurdles Troubleshoot in Resource-Limited Settings

To overcome the initial barrier of nucleic acid extraction, a transformative innovation is the development of "Direct LAMP," which bypasses traditional purification. Clinical samples can be added directly to LAMP reactions using optimized buffers or simple heat-inactivation steps (95°C for 5 minutes) to release viral RNA while neutralizing inhibitors [12,13]. This method allows for "sample-to-result" in under 30 minutes, a critical speed for high-traffic clinics.

To solve the cold-chain logistics issue, manufacturers are now lyophilizing (freeze-drying) the LAMP master mix into single-use beads or "Lab-on-a-Disc" formats [14,15]. These reagents remain stable at room temperature for over a year. In addition, the use of a "warm-start" polymerase that remains inactive at room temperature prevents non-specific polymerization during reaction preparation [16,17].

Lastly, to address the fundamental challenges of intricate primer architecture and non-specific amplification, researchers have developed several biochemical strategies. The addition of macromolecular crowding agents, such as polyethylene glycol (PEG), can stabilize precisely-bound duplexes while reducing inter-primer contact, effectively increasing the limit of detection and reducing false positive rates [18]. Other additives, such as pullulan and tetramethylammonium chloride (TMAC), have been shown to enhance specificity when targeting closely related fungal or bacterial species. Furthermore, to address the residual contamination issue due to reaction contamination, researchers employed mitigation strategies such as the use of the uracil-DNA glycosylase (UDG) enzyme and dUTP to degrade contaminant amplicons, as well as the transition to a closed-tube reaction format [12].

Complementing these biochemical approaches, a significant hardware innovation to further mitigate contamination and specificity issues is the systematically improved chip-based LAMP platform. By covalently immobilizing primers onto the surface of an anodic aluminum oxide (AAO) nanopore, the amplification process is physically restricted to the chip. This approach not only prevents the release of aerosolized amplicons but also allows for label-free optical detection via interference fringe shifts, reducing the assay time to under 20 minutes [19].

Field Implementation and Health System Resilience

The real-world application of LAMP diagnostics has provided critical lessons in maintaining health system resilience during crises. The EXPANDIA project, which established a network of community laboratories across sub-Saharan Africa, highlighted the operational superiority of LAMP over qPCR in resource-limited settings. In many regional clinics, electricity availability is often inconsistent. Field reports from the EXPANDIA project indicate that colorimetric LAMP testing remained reliable during power outages that would typically compromise qPCR-based assays.2 The ability to run the reaction in a simple water bath or heating block offers a significant advantage in areas where sophisticated thermal cyclers cannot be maintained.1 Furthermore, the transition to "cold-chain free" reagents, achieved through

ISSN: 3123-3708

desiccation or lyophilization, can simplify logistical requirements and reduce procurement costs [20].

The integration of Loop-mediated Isothermal Amplification into the global diagnostic framework is a strategic step towards achieving universal health coverage. By addressing technical limitations through CRISPR-Cas integration and AI-assisted design, LAMP has matured into a robust platform capable of meeting the stringent requirements of both central laboratories and remote clinics. The success of projects like EXPANDIA proves that the transfer of molecular technology is not merely a matter of providing equipment, but requires a holistic approach that includes personnel training, local manufacturing, and regulatory alignment. As the world prepares for future pandemics and continues to combat endemic diseases, the decentralization of diagnostic power through isothermal technology will be a cornerstone of infectious disease surveillance and control [5].

References

1. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, Hase T. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000;28(12):e63.
2. Mori Y, Notomi T. Loop-mediated isothermal amplification (LAMP): a rapid, accurate, and cost-effective diagnostic method for infectious diseases. J Infect Chemother. 2009;15(2):62–69.
3. Diagnostic accuracy of loop-mediated isothermal amplification. PHRAJ [Internet]. [accessed on April 9, 2026]. Available from: https://journal-iasssf.com/index.php/PHRAJ/article/download/2247/1561
4. Advancements and applications of loop-mediated isothermal amplification technology: a comprehensive overview. Front Microbiol [Internet]. [accessed on April 9, 2026]. Available from: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1406632/full
5. Loop-Mediated Isothermal Amplification (LAMP) for the Diagnosis of High-Burden Viral Diseases in Resource-Limited Countries. MDPI Pathogens [Internet]. [accessed on April 9, 2026]. Available from: https://www.mdpi.com/2076-0817/15/3/248
6. Accuracy of Loop-Mediated Isothermal Amplification for Diagnosis of Human Leptospirosis in Thailand. PMC[Internet]. [accessed on April 9, 2026]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3062458/
7. Ptitsyn KG, Khmeleva SA, Kurbatov LK, Timoshenko OS. Lamp Primer Designing Software: The Overview. Biomed Chem Res Methods. 2024;7(4):e00226. Available from: http://www.bmc-rm.org/index.php/BMCRM/article/view/226/613
8. Boza JM, et al. Comparison and Optimization of Simple DNA Extraction Methods for LAMP-Based Point-of-Care Applications. ACS Omega. 2024;9(33):38855–38863.
9. Beissner M, Phillips RO, Battke F, et al. Loop-Mediated Isothermal Amplification for Laboratory Confirmation of Buruli Ulcer Disease—Towards a Point-of-Care Test. PLOS Negl Trop Dis. 2015;9(11):e0004219.
10. Chander Y, Koelbl J, Puckett J, et al. A novel thermostable polymerase for RNA and DNA loop-mediated isothermal amplification (LAMP). Front Microbiol. 2014;5:395.
11. Diverse methods of reducing and confirming false-positive results of loop-mediated isothermal amplification assays: A review. PubMed [Internet]. [accessed on April 9, 2026]. Available from: https://pubmed.ncbi.nlm.nih.gov/37858542/

ISSN: 3123-3708

12. Li Z, et al. Extraction-free LAMP assays for generic detection of Old World Orthopoxviruses and specific detection of Mpox virus. Sci Rep. 2023;13(1):21093.
13. Gärtner K, et al. A fast extraction-free isothermal LAMP assay for detection of SARS-CoV-2 with potential use in resource-limited settings. Virol J. 2022;19(1):77.
14. Jothinarayanan N, Karlsen F, Roseng LE. Characterization and validation of a lyophilized Loop-Mediated Isothermal Amplification method for the detection of Esox lucius. Research Square. 2023. Available from: https://doi.org/10.21203/rs.3.rs-3125134/v1
15. Lehnert T, Gijs MAM. Microfluidic systems for infectious disease diagnostics. Lab Chip. 2024;24:1441-1493.
16. Capron A, et al. In Situ Processing and Efficient Environmental Detection (iSPEED) of tree pests and pathogens using point-of-use real-time PCR. PLOS ONE. 2020;15(12):e0226863.
17. Wu X, et al. A warm-start digital CRISPR/Cas-based method for the quantitative detection of nucleic acids. Anal Chim Acta. 2022;1196:339494.
18. Polyethylene glycol modified LAMP assay enables sensitive and specific clinical detection of varicella-zoster virus. PMC [Internet]. [accessed on April 9, 2026]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12722439/
19. A Systematically Enhanced LAMP Chip for Rapid, Sensitive, and Contamination-Free Pathogen Detection. PMC[Internet]. [accessed on April 9, 2026]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12921607/
20. A Blueprint for Resilience: EXPANDIA and the Future of Diagnostics in Low-Resource Settings. Technology Networks [Internet]. [accessed on April 9, 2026]. Available from: https://www.technologynetworks.com/immunology/articles/a-blueprint-for-resilience-expandia-and-the-future-of-diagnostics-in-low-resource-settings-410141

ISSN: 3123-3708